Recent advances in medical dermatology.
Collectively, new developments in the field of medical dermatology will ultimately lead to improved patient care. We review several new findings in the dermatologic literature including the following: new questions regarding the malignant potential of anti-tumor necrosis factor agents, which are widely used for the treatment of moderate to severe psoriasis as well as psoriatic arthritis; anti-interleulin-12, a promising anticytokine for the treatment of psoriasis; diagnostic advances in the detection of latent Mycobacterium tuberculosis; advances in the primary prevention of human papillomavirus and herpes zoster; and new therapeutic options with existing medications for neuropathic pain and pruritus.
Clark
Lily N
LN
Department of Dermatology, Mount Sinai School of Medicine, New York, NY 10029, USA. lily.clark@mssm.edu
Lebwohl
Mark
M
D003879:Dermatologic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D003880:Dermatology / Q000379:methods* / Q000639:trends; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods; D053061:Herpes Zoster Vaccine; D006801:Humans; D007155:Immunologic Factors / Q000009:adverse effects / Q000627:therapeutic use; D018664:Interleukin-12 / Q000037:antagonists & inhibitors; D009161:Mycobacterium / Q000302:isolation & purification; D009164:Mycobacterium Infections / Q000175:diagnosis; D010146:Pain / Q000188:drug therapy; D053918:Papillomavirus Vaccines; D011565:Psoriasis / Q000188:drug therapy; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D003879:Dermatologic Agents; D053061:Herpes Zoster Vaccine; D007155:Immunologic Factors; D053918:Papillomavirus Vaccines; D014409:Tumor Necrosis Factor-alpha; D018664:Interleukin-12